Connect with us

Featured

Manafort Breached Plea Deal, Says Mueller & The Gang

Daniel Chase

Published

on

stock_price_mueller

No one likes a sore loser, but when the reason for losing might involve Russian collusion, the losers have every right to raise suspicion. In October 2016, the US Government publicly announced that it was fairly confident Russia was responsible for the hacking of the Democratic National Committee, resulting in the release of thousands of stolen emails, many of which belonged to former Secretary of State and Democratic Presidential nominee Hillary Clinton. If you only ever hear about politics from the opening monologues of Saturday Night Live, you’ve at least heard something about Hillary’s emails in the last two years. Following the Russian breach of the DNC, President Trump’s campaign and transition teams were accused of colluding with Russia to influence the US election. 

If you remember the Cambridge Analytica scandal, which saw millions of Facebook (FB) user data exposed and sold to political action committees (PACs) to create targeted ads in favor of their candidates, specifically, then Republican nominee, Donald Trump. We all know that Trump secured the presidency, but a year into his new position, the U.S. Justice Department announced its plans to conduct a federal investigation into Russia’s potential meddling in the 2016 election. 

Democrats begged for someone outside the Justice Department to handle the investigation and, at the time, Attorney General Jeff Sessions had already suspiciously recused himself:

“By the virtue of the authority vested in me as Acting Attorney General, in order to discharge my responsibility to provide supervision and management of the Department of Justice, and to ensure a full and through investigation of the Russian government’s efforts to interfere in the 2016 presidential election, I hereby order…Robert S. Mueller III is appointed to serve as Special Counsel for the United States Department of Justice.”

Rod. J Rosenstein, Acting US Attorney General, May 2017

Assuming my premonitions about your political know-how stemming from exposure to political satire on television, I can only guess that you’ve heard one thing or another about the Mueller investigation. Let me preface all of this by saying that the entire investigation seems fishy. For example, Mueller has viciously pursued Paul Manafort, a former Trump staffer during the 2016 campaign, and has since accused him of money laundering, failure to disclose financial assets, and false statements regarding work for the government of Ukraine, all prior to Manafort’s joining the Trump campaign team, according to Vox. 

Over the course of the last year, Mueller has grilled and interrogated countless potential suspects to discover if, in fact, the Trump administration colluded with Russia to help secure the presidency for Donald Trump. Manafort, President Trump’s campaign chairman, is now being accused of lying to federal investigators in breach of a plea agreement he signed two months ago, according to a court filing released by The New York Times on Monday. 

“…After signing the plea agreement, Manafort committed federal crimes by lying to the Federal Bureau of Investigation and the Special Counsel’s Office on a variety of subject matters, which constitute breaches of the agreement…As the defendant has breached the plea agreement, there is no reason to delay is sentencing herein…”

Joint Status Report filed by Robert Mueller

President Trump has, on multiple occasions, referred to the Mueller investigation as a “phony witch hunt, and that Mueller is “viciously ruining lives” for the people he’s investigated, but, given that we already know our president to be more reactionary than he’d like to admit, it’s only  natural that he feels this way about someone attempting to uncover information that would prove he asked the Kremlin to give him some campaign assistance. 

Several media outlets believe Mueller’s investigation will come to a head soon. 

Continue Reading
Click to comment

Featured

Stock Price Newsletter – November 22, 2019

Joe Samuel

Published

on

stock price newsletter

Active Biotech Stocks To Watch As Markets Flirt With New Highs

Biotech stocks are often regarded as safe due to the simple fact that it is a sector that has grown across the board for quite some time. However, in addition, the biotech sector has the potential to generate handsome gains if an investor ends up choosing the right stock.

Click Here To Read More


Streaming Stocks Take Aim At Winning The Content War

The emergence of competition for streaming services from other corporate giants like Disney has started to raise eyebrows. It has been projected that the industry is going to be worth $124.57 billion by 2025. That being said, there may be ample opportunity for investors. Here is a look at a few tech stocks to watch that could be set to prove themselves on this new battlefield.

See For Yourself


Defense Stocks in Focus This Week

It is a well-known fact that the United States has the biggest defense budget in the world and the budget rises every year. That’s is why defense stocks are almost always in demand. These are companies that often win mega contracts from the American government and are immune from the volatile swings of the market.

Continue Reading

Continue Reading

Biotechnology

Active Biotech Stocks To Watch As Markets Flirt With New Highs

A. Lawrence

Published

on

biotech stocks to watch

Biotech stocks is often regarded as safe due to the simple fact that it is a sector that has grown across the board for quite some time. However, in addition, the biotech sector has the potential to generate handsome gains if an investor ends up choosing the right stock.

Investors need to watch the market closely and be aware of the latest news from the sector in order to make the best choices. Here is a look at 3 biotech stocks that turned heads in the biotech sector this week.

PharmaCyte Biotech (PMCB)

PharmaCyte Biotech (PMCB) is in the prep phase of clinical trials and readying to complete its Investigational New Drug Application for the FDA.  Whether you’re new to biotech stocks or a seasoned vet, you should understand how important milestones like this are for a company.

David A. Judd, a cellular biologist and a member of PharmaCyte’s Medical and Scientific Advisory Board, was recently interviewed. Right now, PharmaCyte Biotech (PMCB) is putting together the necessary material for its planned clinical trial for inoperable pancreatic cancer, one of the most deadly forms of cancer today. Though there has been a targeted focus on Pancreatic cancer with PharmaCyte, its diabetes application may also have promise according to Judd.

“I think diabetes is where this type of technology really lends itself to the application. The key is to develop the right type of cell line to treat Type 1 and insulin-dependent Type 2 diabetes. There are several cell lines being explored by PharmaCyte simultaneously to do this. Selecting the right cell line to become our leading product candidate to treat diabetic patients in need of insulin is key to the success of PharmaCyte’s Diabetes Program.”

As one report puts it, “Clinical trials are essential for the development of new treatments, and PharmaCyte will enter this upcoming trial with two essential goals in mind—the future of its pancreatic cancer treatment and the future of its technology.”

For more on PharmaCyte, Click Here

VIVUS (VVUS)

The first biotech stock to consider here is that of VIVUS, Inc. (NASDAQ:VVUS), which has rallied on Wednesday on the back of a major announcement from the company. The stock rallied by 3% this morning in premarket trade after the results were announced from the Phase 1 clinical trial of its product Qsymia. The medicine in question is a capsule and is meant for people who suffer from binge eating disorder.

It should be noted that medicine is currently approved in the United States when used by people in order to reduce calories in their diets. It is a major development for VIVUS and it is no surprise that the stock rallied today.

Diffusion Pharmaceuticals (DFFN)

The other biotech stock that is worth including in the watch list is that of Diffusion Pharmaceuticals Inc (NASDAQ:DFFN), which made solid gains yesterday on the back of the announcement of positive preliminary data from the Phase 3 clinical trial of Trans Sodium Crocetinate (TSC). The medicine is meant for treating inoperable glioblastoma and in the results, it has been revealed that patients recorded a median survival duration of as long as 14.3 months.

Historically, the standard survival duration is only 9.2 months. The results triggered a rally in the stock and the Diffusion stock soared by as much as 67.60%.

list of healthcare stocks to watch

Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 10/15/2019. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 10/16/2019 – 11/15/2019.We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer.

Continue Reading

Featured

Defense Stocks in Focus This Week

Joe Samuel

Published

on

defense stocks to watch weapons detection

While Many Watch Marijuana Stocks, Defense Gets Another Push

It is a well-known fact that the United States has the biggest defense budget in the world and the budget rises every year. That’s is why defense stocks are almost always in demand. These are companies that often win mega contracts from the American government and are immune from the volatile swings of the market.

Even if the economic situation is weak, the government will continue to spend on defense. Therefore these stocks are so attractive for investors. Here is a look at three penny stocks that are worth tracking at this point in time.

Liberty Defense Holdings (SCAN.V) (LDDFF)

There have been more mass shootings this year in the United States than there have been days in the year. Over 330 mass shootings [1], to be exact. This is becoming a huge issue that is costing precious lives and could see billions of dollars spent to fix this situation.

Liberty Defense (TSX: SCAN.V) (OTC: LDDFF) plans to address this issue using HEXWAVE, a next-generation high-tech security scanning system. It will use advanced, low-power radar, 3D-imaging, and Artificial Intelligence (AI) to screen people at public gatherings such as sports games, unobtrusively. The company itself has been making paramount progress this quarter.

Most recently the company signed a collaboration agreement with Port Tampa Bay to beta test HEXWAVE. Between the years 2007 and 2017, total cruise ship passenger capacity grew by 25 percent in North America, with the following 10 years estimated to see a further 41 percent increase, according to a 2017 report. So this move could prove to be well-timed for a company like Liberty Defense (TSX: SCAN.V) (OTC: LDDFF).

Also, keep in mind that they’ve also got agreements in place with FC Bayern Munich’s Allianz Arena in Germany, Rogers Arena in Vancouver, British Columbia, Maryland Stadium Authority’s Camden Yards Complex, and in the state of Utah. There’s also projects with the Virginia Division of Capitol Police, in Sleiman shopping centers, in a Hindu temple, in the Metro Toronto Convention Centre, in Toronto Pearson International Airport, and with the University of Wisconsin Police Department. To say that they’ve laid the groundwork may be an understatement and results of these beta tests are highly anticipated by the company.

Air Industries Group (AIRI)

The first defense stock to consider is that of Air Industries Group Inc (NYSEAMERICAN:AIRI). The company is involved in aerospace and defense space. Air is best known for manufacturing, designing and selling products that are meant for flight safety. The Air stock has done particularly well this year and has soared by as much as 65% thus far. It is important to point out that Air counts some of the biggest names in the industry among its clients.

Products made by the company are currently used in Sikorsky’s UH-60 Black Hawk, Lockheed Martin’s F-35 Joint Strike Fighter, Northrop Grumman’s E2 Hawkeye, Boeing’s 777, Airbus’ 380 commercial airliners, and the US Navy F-18 and USAF F-16 fighter aircraft. It also supplies equipment for different United States State Department Branches. It goes without saying that this is a stock that should be tracked closely.

Astrotech Corp (ASTC)

The other defense stock that should be in investors’ watch lists is that of Astrotech Corp (NASDAQ:ASTC). On November 14, it emerged that a product made by the company’s subsidiary 1st Detect has been chosen to conduct live screening at Miami International Airport by the U.S.

Department of Homeland Security (DHS) Transportation Security Administration (TSA). The product in question is TRACER 1000 and ever since the announcement was made, there has been an impressive rally in the Astrotech stock. That stock rallied by as much as 80% in one day.

weapons detection stocks security stocks

Disclaimer:Pursuant to an agreement between MIDAM VENTURES, LLC and Liberty Defense Holdings Inc. Midam was hired for a period from 06/1/2019 – 9/30/2019 to publicly disseminate information about Liberty Defense Holdings Inc. including on the Website and other media including Facebook and Twitter. We were paid $250,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid $75,000 (CASH) by Liberty Defense Holdings AND HAVE EXTENDED coverage for a period from 11/1/2019 – 11/30/2019. We may buy or sell additional shares of Liberty Defense Holdings Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. For previous compensation see our FULL DISCLAIMER HERE.

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


Privacy Policy

We keep all user information pricate & promise to never spam.*

Stock Price Free Text List

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com